QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Kirby, S. Articles by Eisenhauer, E. A. Search for Related Content PubMed PubMed Citation

Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group

Nova Scotia Cancer Centre, Halifax, NS B3H 1V7, Canada (S.K.); Ottawa Regional Cancer Centre, Ottawa, ON K1H 8L6, Canada (S.Z.G.); Princess Margaret Hospital, Toronto, ON M5G 2M9, Canada (W.M.); London Regional Cancer Centre, London, ON N6A 4L6, Canada (C.W.); Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada (P.F.); Tularik, Inc., South San Francisco, CA 94080, USA (J.A., R.S., M.W.); National Cancer Institute of Canada, Clinical Trials Group, and Queen's University Kingston, ON K7L 3N6, Canada (J.P., E.A.E.)

² Address correspondence to Sarah Kirby, Nova Scotia Cancer Centre, Dalhousie University, 464 Bethune Building, 1278 Tower Road, Halifax, NS B3H 2Y9, Canada (skirby2{at}dal.ca).

Abstract

We studied the activity of T138067-sodium in patients with malignant gliomas. T138067-sodium is a unique new chemotherapy agent that inhibits microtubule formation by binding irreversibly and specifically to ß₁, ß_2, and ß₄ isotypes of ß-tubulin, causing cell arrest at G₂/M and inducing apoptosis. Patients with recurrent anaplastic astrocytoma or glioblastoma multiforme were treated intravenously with 330 mg/m² of T138067-sodium weekly. Treatment was continued until the patient experienced either unacceptable toxicity or progressive disease. Patients had to have histologically proven glioma, have bidimensionally measurable disease at least 1 cm x 1 cm, and have received no more than one prior adjuvant chemotherapy. No chemotherapy or radiotherapy for recurrent disease was permitted. Nineteen patients entered the trial. One patient was found to be ineligible. There were two patients with anaplastic astrocytoma and 16 with glioblastoma multiforme. Only two patients had received prior adjuvant chemotherapy. The first seven patients had full pharmacokinetic sampling. No dose-limiting toxicity was seen, and pharmacokinetic results were consistent with those from nonglioma patients. The most common drug-related effects were fatigue (33%), nausea (28%), neutropenia (28%), and anorexia (17%). No patients stopped the study because of toxicity. No responses were seen in the 15 eligible patients who completed at least one cycle. Three patients had stable disease with a median duration of 2.6 months. Our results suggest that given in this dose and schedule T138067-sodium does not have activity in this population of anaplastic astrocytoma and glioblastoma multiforme.